This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).
*Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, Spectrum Health Medical Group and Michigan State University College of Human Medicine, Grand Rapids, Michigan
†Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
‡Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Center and Solove Research Institute, Columbus, Ohio
The authors declare that they have nothing to disclose.
Correspondence: Leigh G. Seamon, DO, MPH, Gynecologic Oncology, Lemmen-Holton Cancer Pavilion, Suite 2220, Grand Rapids, MI. E-mail: Leigh.Seamon@spectrumhealth.org